MyFinsight
Home
Blog
About
Proceeds from the sale of
convertible notes
$250,000K
Proceeds from the
issuance of common stock...
$143,750K
Proceeds from issuance of
common stock under...
$1,270K
(126.38%↑ Y/Y)
Proceeds from issuance of
common stock upon...
$577K
(-81.14%↓ Y/Y)
Net cash provided by
financing activities
$325,121K
(3159.03%↑ Y/Y)
Canceled cashflow
$70,476K
Net increase
(decrease) in cash and cash...
-$11,360K
(-164.07%↓ Y/Y)
Canceled cashflow
$325,121K
Maturities of marketable
securities
$148,804K
(-50.87%↓ Y/Y)
Share-based compensation
expense
$16,984K
(-19.37%↓ Y/Y)
Accrued and other
liabilities
$6,113K
(162.88%↑ Y/Y)
Loss on
extinguishment of debt
-$4,449K
Non-cash interest
expense
$2,538K
Change in fair value of
derivative liability
-$1,190K
Depreciation and
amortization
$117K
(-49.13%↓ Y/Y)
Non-cash lease expense
$2K
(111.76%↑ Y/Y)
Prepayment of long-term
debt
$54,700K
Payments of issuance
costs associated with...
$8,270K
Payments of issuance
costs associated with...
$7,506K
Net cash provided by
(used in) investing...
-$231,157K
(-231.50%↓ Y/Y)
Canceled cashflow
$148,804K
Net cash used in
operating activities
-$105,324K
(37.32%↑ Y/Y)
Canceled cashflow
$31,393K
Purchases of marketable
securities
$378,655K
(198.16%↑ Y/Y)
Purchase of property and
equipment
$1,306K
(920.31%↑ Y/Y)
Net loss
-$127,119K
(32.26%↑ Y/Y)
Accounts payable
-$5,204K
(-181.36%↓ Y/Y)
Prepaid expenses and
other assets
$2,402K
(143.84%↑ Y/Y)
Accretion and
amortization of...
$1,451K
(-62.53%↓ Y/Y)
Other liabilities
-$342K
Back
Back
Cash Flow
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)
source: myfinsight.com